Zacks Research Issues Optimistic Estimate for CPRX Earnings

Key Points

• Zacks Research raised its Q2 2026 earnings estimate for Catalyst Pharmaceuticals to $0.58 per share, reflecting a slight increase from their previous estimate of $0.57.
• Catalyst Pharmaceuticals received a "strong-buy" rating from Cantor Fitzgerald, contributing to a consensus buy rating among analysts and an average price target of $32.83.
• Insider transactions revealed that two company insiders sold a significant number of shares, amounting to over $1 million, indicating a decrease in their positions within the company.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Zacks Research upped their Q2 2026 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a note issued to investors on Tuesday, July 22nd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings of $0.58 per share for the quarter, up from their prior forecast of $0.57. The consensus estimate for Catalyst Pharmaceuticals' current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals' Q3 2026 earnings at $0.64 EPS, Q4 2026 earnings at $0.64 EPS, FY2026 earnings at $2.42 EPS, Q1 2027 earnings at $0.74 EPS, Q2 2027 earnings at $0.62 EPS and FY2027 earnings at $2.60 EPS.

Separately, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Six investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $32.83.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock traded up $0.35 during trading hours on Friday, reaching $21.15. 449,434 shares of the company were exchanged, compared to its average volume of 1,284,919. Catalyst Pharmaceuticals has a 1 year low of $15.34 and a 1 year high of $26.58. The stock's fifty day moving average is $22.88 and its 200 day moving average is $22.89. The firm has a market cap of $2.58 billion, a PE ratio of 13.46, a PEG ratio of 0.85 and a beta of 0.66.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 200,000 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total value of $4,736,000.00. Following the transaction, the insider owned 68,873 shares of the company's stock, valued at $1,630,912.64. This represents a 74.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Preethi Sundaram sold 2,324 shares of the stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total value of $61,376.84. Following the completion of the transaction, the insider directly owned 42,681 shares in the company, valued at $1,127,205.21. This trade represents a 5.16% decrease in their position. The disclosure for this sale can be found here. Insiders sold 247,924 shares of company stock worth $5,879,369 in the last three months. 10.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals in the fourth quarter valued at $29,000. Sound Income Strategies LLC acquired a new position in Catalyst Pharmaceuticals in the first quarter valued at $64,000. GAMMA Investing LLC boosted its stake in Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 579 shares in the last quarter. Quarry LP acquired a new position in Catalyst Pharmaceuticals in the fourth quarter valued at $104,000. Finally, New Vernon Capital Holdings II LLC acquired a new position in Catalyst Pharmaceuticals in the fourth quarter valued at $122,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.